Literature DB >> 14526124

Gene therapy for lung cancer.

Eric B Haura1, Eduardo Sotomayor, Scott J Antonia.   

Abstract

Lung cancer continues to be the largest killer of Americans due to cancer. Although progress has been made, with advances in chemotherapy, the majority of patients diagnosed with lung cancer ultimately succumb to the disease. A better understanding of the molecular pathogenesis of lung cancer is demonstrating how alterations in oncogenes and tumor suppressor genes control lung cancer initiation, growth, and survival. In this article, attempts to target molecular alterations in lung cancer using gene therapy techniques are reviewed. These include introducing suicide genes into tumor cells, replacement of defective tumor suppressor genes, inactivating oncogenes, and immunotherapy-based approaches using gene therapy technology. The major barrier for these techniques continues to be the inability to specifically target tumor cells while sparing normal cells. Nonetheless, these approaches are likely to yield important biologic and clinical data which will further the progress of lung cancer treatment.

Entities:  

Mesh:

Year:  2003        PMID: 14526124     DOI: 10.1385/MB:25:2:139

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.860


  68 in total

1.  Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene.

Authors:  A Inoue; K Narumi; N Matsubara; S Sugawara; Y Saijo; K Satoh; T Nukiwa
Journal:  Cancer Lett       Date:  2000-08-31       Impact factor: 8.679

2.  Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.

Authors:  J Nemunaitis; J T Holmlund; M Kraynak; D Richards; J Bruce; N Ognoskie; T J Kwoh; R Geary; A Dorr; D Von Hoff; S G Eckhardt
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

3.  Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge.

Authors:  D J Cole; M C Wilson; P L Baron; P O'Brien; C Reed; K Y Tsang; J Schlom
Journal:  Hum Gene Ther       Date:  1996-07-10       Impact factor: 5.695

4.  Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function.

Authors:  J Ishizaki; J R Nevins; B A Sullenger
Journal:  Nat Med       Date:  1996-12       Impact factor: 53.440

Review 5.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

6.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

Authors:  J W Simons; B Mikhak; J F Chang; A M DeMarzo; M A Carducci; M Lim; C E Weber; A A Baccala; M A Goemann; S M Clift; D G Ando; H I Levitsky; L K Cohen; M G Sanda; R C Mulligan; A W Partin; H B Carter; S Piantadosi; F F Marshall; W G Nelson
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

7.  Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells.

Authors:  Y A Zhang; J Nemunaitis; A W Tong
Journal:  Mol Biotechnol       Date:  2000-05       Impact factor: 2.695

8.  Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice.

Authors:  Y A Zhang; J Nemunaitis; K J Scanlon; A W Tong
Journal:  Gene Ther       Date:  2000-12       Impact factor: 5.250

Review 9.  Gene therapy for lung disease: hype or hope?

Authors:  S M Albelda; R Wiewrodt; J B Zuckerman
Journal:  Ann Intern Med       Date:  2000-04-18       Impact factor: 25.391

10.  Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells.

Authors:  R Pieper; R E Christian; M I Gonzales; M I Nishimura; G Gupta; R E Settlage; J Shabanowitz; S A Rosenberg; D F Hunt; S L Topalian
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

View more
  2 in total

1.  "Marker of Self" CD47 on lentiviral vectors decreases macrophage-mediated clearance and increases delivery to SIRPA-expressing lung carcinoma tumors.

Authors:  Nisha G Sosale; Irena I Ivanovska; Richard K Tsai; Joe Swift; Jake W Hsu; Cory M Alvey; Philip W Zoltick; Dennis E Discher
Journal:  Mol Ther Methods Clin Dev       Date:  2016-12-07       Impact factor: 6.698

2.  PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium.

Authors:  Maytal Bivas-Benita; Stefan Romeijn; Hans E Junginger; Gerrit Borchard
Journal:  Eur J Pharm Biopharm       Date:  2004-07       Impact factor: 5.571

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.